anaplastic oligoastrocytoma
anaplastic oligoastrocytoma
Explore linked clinical trials. Standard reference: MONDO:00167033 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic astrocytoma, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, astrocytoma (excluding glioblastoma), diffuse astrocytoma, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, oligoastrocytoma, oligodendroglioma, primitive neuroectodermal tumor | Active, not recruiting | Phase 2 | 2026-07-28 | NCT03180502 | |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic oligoastrocytoma, anaplastic oligodendroglioma, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, grade II glioma, grade III glioma, neoplasm, neuroepithelial neoplasm, oligoastrocytoma, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-07-16 | NCT04623931 | |
| Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA | Brain Tumor, Recurrent, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic astrocytoma, anaplastic oligoastrocytoma, astrocytoma (excluding glioblastoma), brain cancer, brain disorder, central nervous system cancer, central nervous system disorder, epithelial neoplasm, glioblastoma, glioma, neoplasm, nervous system disorder, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-04-13 | NCT02800486 |